PubHawk
PLOS Glob Public Health May 2022 PMID 36962423

Evaluating the potential cost-effectiveness of microarray patches to expand access to hepatitis B birth dose vaccination in low-and middle-income countries: A modelling study.

Christopher P Seaman, Mercy Mvundura, Collrane Frivold, Christopher Morgan, Courtney Jarrahian, Jess Howell, Margaret Hellard, Nick Scott

Download social card

Mentions

3
Peak: 2 in May 2022
across 2 sources since May 2022

Extended reach

12,720
potential audience

Total likes

4

Video views

33

Mentions per month

May 2022 – Jun 2023

Where it's discussed

  • X / Twitter2 posts
  • YouTube1 videos

AI synopsis

What people are saying

The posts mainly express strong agreement with the article's findings, using words like 'highly cost-effective' and 'game-changing,' reflecting both interest and belief in its impact. For example, one highlights that MAPs could expand vaccine reach despite higher costs, showing deep engagement with the research's potential, while others emphasize the importance of this innovation for public health, underscoring its high impact.

AgreementStrong agreement

The majority of discussions strongly endorse the study, emphasizing the potential of MAPs to improve vaccination coverage, even at higher costs.

InterestHigh interest

Posts show high interest, highlighting the importance of innovative vaccination methods in low- and middle-income countries.

EngagementModerate engagement

While most posts briefly summarize findings, some delve into implications for healthcare policy, indicating active engagement.

ImpactHigh impact

Discussions suggest the research could significantly influence vaccination strategies and health outcomes in resource-limited settings.

Abstract in brief

  • Microarray patches (MAPs) could help increase hepatitis B birth dose vaccination in low- and middle-income countries by overcoming current delivery barriers outside health facilities.
  • The study evaluated the cost-effectiveness of using MAPs at different prices and use cases, finding they can significantly reduce disease burden, especially when used to expand coverage beyond current methods.
  • While MAPs are more costly per dose than current vaccines, they may still provide good value, particularly when used to reach more newborns outside health facilities, with potential savings per health impact.
Read the full abstract

Top posts

Most liked on X and Bluesky
PLOS Global Public Health
@PLOSGPH · X

JUST PUBLISHED: Christopher P. Seaman and colleagues' findings suggest even at higher procurement costs, microarray patches (MAPs) are likely to represent a highly cost-effective or cost-saving mechanism to expand reach of birth dose vaccination in LMICs. https://t.co/dsLBG3aBde https://t.co/Fu1Z93doOH

May 23, 2022 · 2 likes · 2 shares · 11,038 followers View post →
Julia Robinson
@JuliaE_Robinson · X

RT @PLOSGPH: JUST PUBLISHED: Christopher P. Seaman and colleagues' findings suggest even at higher procurement costs, microarray patches (M…

May 23, 2022 · 2 shares · 1,641 followers View post →

All mentions

Julia Robinson
@JuliaE_Robinson · X

RT @PLOSGPH: JUST PUBLISHED: Christopher P. Seaman and colleagues' findings suggest even at higher procurement costs, microarray patches (M…

May 23, 2022 · 2 shares · 1,641 followers View post →
PLOS Global Public Health
@PLOSGPH · X

JUST PUBLISHED: Christopher P. Seaman and colleagues' findings suggest even at higher procurement costs, microarray patches (MAPs) are likely to represent a highly cost-effective or cost-saving mechanism to expand reach of birth dose vaccination in LMICs. https://t.co/dsLBG3aBde https://t.co/Fu1Z93doOH

May 23, 2022 · 2 likes · 2 shares · 11,038 followers View post →